1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,252 | 1,256 | 09:32 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Nanoform Finland Plc - Manager's Transactions - Edward Hæggström | 1 | Cision News | ||
| Mi | Nanoform Finland Plc - Manager's Transactions - Peter Hänninen | 1 | Cision News | ||
| Mi | Nanoform Finland Plc - Manager's Transactions - Albert Hæggström | 1 | Cision News | ||
| Mi | The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees | 1 | Cision News | ||
| Mi | Nanoform Finland Plc - Managers' transactions - Antonio Da Silva | 3 | Cision News | ||
| 19.11. | Nanoform Finland Plc - Manager's Transactions - Peter Hänninen | 2 | Cision News | ||
| 19.11. | Nanoform Finland Plc - Manager's Transactions - Albert Hæggström | 2 | Cision News | ||
| 18.11. | Nanoform Finland Oyj: Nanoform Q3 2024 report: Record number of new projects signed | 318 | GlobeNewswire (Europe) | Company Announcement
Nanoform Finland Plc
November 18, 2024
08:10 a.m. Finnish time / 07:10 a.m. Swedish time
Nanoform Q3 2024 report: Record number of new projects signed
A record number of new... ► Artikel lesen | |
| NANOFORM FINLAND Aktie jetzt für 0€ handeln | |||||
| 04.11. | Invitation to Nanoform's Q3 2024 Report Presentation | 2 | Cision News | ||
| 25.10. | Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Company Release | 2 | Cision News | ||
| 22.10. | Share subscriptions based on Nanoform Finland Plc's stock options 2/2019 | 1 | Cision News | ||
| 05.09. | Nanoform and Celanese Expand Collaboration into Long-Acting Biologics Delivery Through Small Implants | 5 | Cision News | ||
| 29.08. | Nanoform Q2 report: All business targets for 2024 on track | 1 | Cision News | ||
| 16.08. | Invitation to Nanoform's Q2 2024 Report Presentation | 1 | Cision News | ||
| 15.08. | Nanoform Collaborates with Takeda on Plasma-derived Therapy Development | 14 | Contract Pharma | ||
| 15.08. | NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT | 797 | PR Newswire | HELSINKI, Aug. 15, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development... ► Artikel lesen | |
| 30.05. | Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned | 539 | PR Newswire | HELSINKI, May 30, 2024 /PRNewswire/ -- Manufacturing of GMP material in Project Nanoenzalutamide commenced. EU/US pivotal studies are planned to start in 4Q24, with the read-out in 1Q25.... ► Artikel lesen | |
| 09.04. | Nanoform and PlusVitech partner to repurpose aprepitant as a treatment for lung cancer | 801 | PR Newswire | Nanoform Finland Plc
April 9, 2024
09.00 EEST / 08.00 CEST
HELSINKI, April 9, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company... ► Artikel lesen | |
| 15.02. | Inside information made public: Nanoform Wins R&D Grant of EUR 4.3M for Research Into Nanoparticle Enabled Formulations for Next Generation Medicines | 635 | PR Newswire | THIS PRESS RELEASE CONTAINS INFORMATION THAT NANOFORM IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SENT FOR PUBLICATION THROUGH THE AGENCY OF... ► Artikel lesen | |
| 26.01. | Inside information made public: Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide | 700 | PR Newswire | THIS PRESS RELEASE CONTAINS INFORMATION THAT NANOFORM IS OBLIGED TO MAKE PUBLIC PURSUANT TO THE EU MARKET ABUSE REGULATION. THE INFORMATION WAS SENT FOR PUBLICATION THROUGH THE AGENCY OF... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 51,10 | +0,20 % | Formycon: Fortschritte erzielt, die nächsten Schritte vorbereitet; mwb research bestätigt KAUFEN | Formycon schloss ein ereignisreiches Jahr mit einer Roundtable-Veranstaltung ab, die von mwb research ausgerichtet wurde und wichtige Meilensteine des Jahres 2024 hervorhob. In der Diskussion wurden... ► Artikel lesen | |
| ONTO INNOVATION | 163,00 | +0,62 % | Oppenheimer Reaffirms "Outperform" Rating for Onto Innovation (NYSE:ONTO) | ||
| KOPIN | 1,217 | -4,77 % | Kopin Aktie: Starke Wachstumsimpulse entdeckt! | Die Kopin Corporation, ein führender Entwickler von Nano-Halbleitern, verzeichnet aktuell eine beachtliche Marktentwicklung. Der Aktienkurs des Technologieunternehmens konnte im letzten Monat einen... ► Artikel lesen | |
| GAUZY | 8,570 | 0,00 % | GAUZY LTD: Gauzy Receives Outstanding Supplier Award for Its Smart-Vision Advanced Driver Assistance System (ADAS) From World's Largest Commercial Bus Manufacturer, Yutong | ||
| VEECO INSTRUMENTS | 26,400 | -0,75 % | PlayNitride qualifies Veeco's Lumina MOCVD system for micro-LED production | ||
| DOTZ NANO | 0,061 | +4,31 % | DOTZ NANO LIMITED: Strategic Collaboration Agreement with Bar-Ilan University | ||
| ZENTEK | 0,870 | -1,14 % | Zentek Provides Update on International Opportunities | GUELPH, ON / ACCESSWIRE / December 12, 2024 / Zentek Ltd. (" Zentek "or the " Company ") (NASDAQ:ZTEK)(TSXV:ZEN), an intellectual property development and commercialization company, has signed a Memorandum... ► Artikel lesen | |
| NANOVIRICIDES | 1,400 | -2,10 % | NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID | SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September... ► Artikel lesen | |
| FENDX TECHNOLOGIES | 0,102 | -9,78 % | FendX Technologies Inc.: FendX Announces RSU Grant | Oakville, Ontario--(Newsfile Corp. - December 19, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX"), a nanotechnology company developing surface protection... ► Artikel lesen | |
| ADVANCE ZINCTEK | 0,460 | +1,32 % | ADVANCE ZINCTEK LIMITED: Change of Director's Interest Notice - Lev Mizikovsky | ||
| ACACIA RESEARCH | 4,060 | 0,00 % | Acacia Research Reports Third Quarter 2024 Financial Results | NEW YORK--(BUSINESS WIRE)--Acacia Research Corporation (Nasdaq: ACTG) ("Acacia" or the "Company"), which acquires and operates businesses across the industrial, energy and technology sectors, today... ► Artikel lesen | |
| LEHNER INVESTMENTS | 0,022 | 0,00 % | EQS-News: LEHNER INVESTMENTS AG: Alpay Ece verstärkt den Vorstand | EQS-News: LEHNER INVESTMENTS AG
/ Schlagwort(e): Personalie
LEHNER INVESTMENTS AG: Alpay Ece verstärkt den Vorstand
25.11.2024 / 16:15 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| NANOFOCUS | 1,240 | 0,00 % | NanoFocus passt Prognose für 2024 an | Die NanoFocus AG hat heute beschlossen, die Prognose für das laufende Jahr anzupassen. Aufgrund von gegenwärtig absehbar deutlich niedrigeren Umsätzen in den Bereichen Semiconductor Asia und Standard/Labor... ► Artikel lesen | |
| RIBER | 2,680 | 0,00 % | RIBER: Solid Business Growth at End-September 2024 | SOLID BUSINESS GROWTH AT END-SEPTEMBER 2024 Revenues up +14% to €18.5mOrder book strengthened to €38.3m (+14%) Bezons, October 30, 2024 - 8:00am - RIBER, the global leader for molecular beam epitaxy... ► Artikel lesen | |
| GOMSPACE | 0,469 | 0,00 % | GomSpace Group AB: GomSpace returns to comprehensive market guidance with strong outlook for 2025 | The company is indicating a year-on-year revenue growth of more than 30%, strong EBITDA improvement, and positive free cashflow for full year 2025. The company will deliver positive free cashflow for... ► Artikel lesen |
NANOFORM FINLAND OYJ gehört der Branche Nanotechnologie an. Der aktuelle Kurs liegt bei 1,222 Euro und damit -2,71 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOFORM FINLAND OYJ finden Sie auf Wallstreet Online.
